

# PRODUCT INFORMATION




## Ziftomenib

Item No. 45139

**CAS Registry No.:** 2134675-36-6  
**Formal Name:** 4-methyl-5-[[4-[[2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl]amino]-1-piperidinyl] methyl]-1-[(2S)-2-[4-(methylsulfonyl)-1-piperazinyl]propyl]-H-indole-2-carbonitrile

**Synonym:** KO-539  
**MF:** C<sub>33</sub>H<sub>42</sub>F<sub>3</sub>N<sub>9</sub>O<sub>2</sub>S<sub>2</sub>  
**FW:** 717.9  
**Purity:** ≥98%  
**Supplied as:** A solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Ziftomenib is supplied as a solid. A stock solution may be made by dissolving the ziftomenib in the solvent of choice, which should be purged with an inert gas. Ziftomenib is slightly soluble (0.1-1 mg/ml) in ethanol and sparingly soluble (1-10 mg/ml) in DMSO.

### Description

Ziftomenib is an inhibitor of the protein-protein interaction between menin and mixed-lineage leukemia 1 (MLL1).<sup>1</sup> It decreases the viability of OCI-AML-3 and MV4-11 acute myeloid leukemia (AML) cells in a concentration-dependent manner. Ziftomenib selectively reduces the viability of p53<sup>R175H</sup>-expressing MOLM-13 leukemia cells and TP53<sup>-/-</sup> MOLM-13 cells over wild-type p53-expressing MOLM-13 cells. Ziftomenib (75 mg/kg) increases survival in a patient-derived xenograft (PDX) mouse model of AML. Formulations containing ziftomenib have been used in the treatment of AML.

### Reference

1. Fiskus, W., Daver, N., Boettcher, S., *et al.* Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1. *Leukemia* **36(11)**, 2729-2733 (2022).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/19/2026

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897

[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM